WuXi Biologics
WuXi Biologics develops and manufactures antibodies for hundreds of clients worldwide, and its WuXi XDC unit is the largest contract maker of antibody-drug conjugates.
Overview
Discovery, cell-line development and GMP manufacture of monoclonal and bispecific antibodies; WuXi XDC (listed separately in Hong Kong, 2268.HK) runs integrated ADC conjugation for a large share of clinical-stage ADCs from both Chinese and Western sponsors. Named in the US BIOSECURE Act; sold its Irish vaccine plant to Merck in 2025. The company behind much of the antibody supply for China's PD-1 and ADC boom.
Pages like this
not linked directly; found by shared links- CompanyJW Therapeutics
Shares Ge Li, WuXi AppTec and the tag china.
- ProductRelmacabtagene autoleucel
Shares WuXi AppTec and the tag china.
- CompanyShanghai Henlius Biotech
Shares Regulatory divergence between regions and the tag china.
- ProductEnvafolimab
Shares Monoclonal antibodies and the tag china.
- ProductAdebrelimab
Shares Monoclonal antibodies and the tag china.
- ProductSugemalimab
Shares Monoclonal antibodies and the tag china.
- TrialHARMONi-A
Shares Bispecific antibodies and the tag china.
- ProductSintilimab
Shares Monoclonal antibodies and the tag china.